Middle East & Africa Point of Care Diagnostics Market Revenue to cross US$ 3,524.0 Million by 2031

According to The Insight Partners' research, the Middle East & Africa Point of Care Diagnostics Market was valued at US$ 1,670.9 Million in 2024 and is expected to reach US$ 3,524.0 Million by 2031, registering a CAGR of 11.3% from 2025 to 2031.

Increasing prevalence of infectious diseases and key product launches and developments are among the critical factors attributed to driving the Middle East & Africa point of care diagnostics market growth.

The surge in infectious diseases globally fuels demand for point-of-care diagnostics. As outbreaks spread rapidly, quick, on-the-spot testing becomes essential to control transmission. This trend drives innovation in compact, user-friendly diagnostic devices. Immediate results enable faster clinical decisions and reduce reliance on centralized labs. Ultimately, the growing disease burden accelerates the shift toward decentralized healthcare solutions. Point-of-care testing (POCT) is critical for the diagnosis, treatment, and prevention of infectious diseases. It can be used to detect major pathogens, including human immunodeficiency virus (HIV), malarial parasites, human papillomavirus (HPV), Ebola, dengue, and Zika viruses, and Mycobacterium tuberculosis (TB bacteria). According to the World Health Organization (WHO) data, 1.3 million people (including 214,000 individuals affected by HIV) succumbed to TB in 2022. Its estimates also indicate that 10.6 million individuals in the world will have TB in 2022, including 3.5 million women, 1.3 million children, and 5.8 million men. Additionally, 30 countries with high TB burdens contributed 86-90% of new TB cases during 2022. Eight countries contributed two-thirds of the total, with India leading the way, followed by the Philippines, China, Indonesia, Pakistan, Nigeria, Bangladesh, and South Africa. As per the WHO, HIV has infected over 39.9 million people worldwide. In 2023, people were diagnosed with HIV, out of which 1.3 million people were newly diagnosed, including 77% adults and 57% children. The rising prevalence of infectious diseases and healthcare-associated infections is intensifying the need for rapid, accurate point-of-care diagnostics. These tools enable early detection, timely treatment, and effective disease management, reducing the strain on healthcare systems. By providing immediate results outside traditional labs, point-of-care testing enhances patient outcomes and helps curb the spread of infections. As infectious disease burdens continue to grow, the adoption of decentralized diagnostic solutions becomes increasingly vital for global health.

On the contrary, the product recalls hamper the growth of the Middle East & Africa point of care diagnostics market.

Middle East & Africa Point of Care Diagnostics Market Segmentation Analysis:

• By Product, the Middle East & Africa Point of Care Diagnostics Market is segmented into Glucose Monitoring, Infectious Disease Testing, Cardio metabolic Testing, Pregnancy And Fertility Testing, Coagulation Testing, Tumor or Cancer Marker Testing, Cholesterol Testing, Urinalysis Testing, Hematology Testing, Thyroid Testing, and Others. The Glucose Monitoring segment is projected to expand at 13.6% CAGR during 2025 - 2031.
• By Glucose Monitoring, the Middle East & Africa Point of Care Diagnostics Market is segmented into Blood Glucose Meter, Lancet, and Strips. The Strips segment is projected to expand at 13.3% CAGR during 2025 - 2031.
• By Infectious Disease Testing, the Middle East & Africa Point of Care Diagnostics Market is segmented into HIV Testing, Influenza Testing, Sexually Transmitted Diseases Testing, Hepatitis C Virus Testing, Tropical Diseases Testing, Respiratory Infection Testing, Hospital Acquired Infections, and Others. The Respiratory Infection Testing segment is projected to expand at 14.6% CAGR during 2025 - 2031.
• By Cardio Metabolic Testing, the Middle East & Africa Point of Care Diagnostics Market is segmented into Cardiac Troponin (cTn) Test, Myoglobin Test, and Others. The Cardiac Troponin (cTn) Test segment is projected to expand at 11.5% CAGR during 2025 - 2031.
• By Purchase Mode, the Middle East & Africa Point of Care Diagnostics Market is segmented into OTC and Prescription. The Prescription segment is projected to expand at 11.0% CAGR during 2025 - 2031
• By Sample, the Middle East & Africa Point of Care Diagnostics Market is segmented into Blood, Urine, and Others. The Blood segment is projected to expand at 11.6% CAGR during 2025 - 2031.
• By End User, the Middle East & Africa Point of Care Diagnostics Market is segmented into Healthcare Facilities, Homecare, and Others. The Healthcare Facilities segment is projected to expand at 11.1% CAGR during 2025 - 2031.
• By Healthcare Facilities, the Middle East & Africa Point of Care Diagnostics Market is segmented into Hospitals and Clinics, Diagnostic Centers, and Others. The Diagnostic Centers segment is projected to expand at 11.4% CAGR during 2025 - 2031.

By country, the Middle East & Africa Point of Care Diagnostics Market is categorized into South Africa, Saudi Arabia, the United Arab Emirates, and the Rest of Middle East & Africa. South Africa is projected to expand at 12.9% CAGR during 2025 - 2031.

Key players operating in the Point of Care Diagnostics Market are Siemens AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Nova Biomedical Corporation, Polymer Technology Systems, Inc. (PTS), and Danaher Corp, among others.

• In January 2025, Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation, a global science and technology innovator, announced today that they have formed an investment partnership with Innovaccer Inc., a leading healthcare artificial intelligence (AI) company.